Τόμος 24 (2010) – Τεύχος 1 – Άρθρο 8 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 24 (2010) – Issue 1 – Article 8 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

2^nd Neonatal Intensive Care Unit, General Hospital Papageorgiou, Aristotle University, Thessaloniki, Hellas

pharmakonpress[at]pharmakonpress[.]gr

2. Bancalari E., Abdenour G.E., Feller R., Gannon J.: Bronchopulmonary dysplasia. J. Pediatr. 95: 819-283 (1979)

3. Shennan A.T., Dunn M.S., Ohlsson A., Lennox K., Hoskins E.M.: Abnormal pulmonary outcomes in premature infants: Prediction from oxygen requirements in the neonatal period. Pediatrics 82: 527 (1988)

4. Bancalari E., Claure N., Sosenko I.R.: Bronchopulmonary dysplasia: changes in pathogenesis, epidemiology and definition. Semin. Neonatol. 8: 63-71 (2003)

5. Rojas M.A., Gonzalez A., Bancalari E., Claure N., Poole C., Silva-Neto G.: Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease. J. Pediatr. 126: 605-610 (1995)

6. Κρεμενόπουλος Γ.Μ.: Βρογχοπνευμονική δυσπλασία. Νεογνολογία. Τα προβλήματα των νεογνών και η αντιμετώπισή τους. Εκδόσεις ARIS, Α. Τριανταφύλλου, Θεσσαλονίκη, (1989).

7. Lemons J.A., Bauer C.R., Oh W., Korones S.B., Papile C.A., Stoll B.J., et al.: Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, January 1995 through December 1996. Pediatrics 107: 1-8 (2001)

8. Collaborative European Multicenter Study Group: Surfactant replacement therapy for severe neonatal respiratory distress syndrome: an international randomized clinical trial. Pediatrics 82: 683-90 (1990)

9. Schwarz R.M., Luby A.M., Scanlon J.W., Kellogg R.J.: Effect of surfactant on morbidity, mortality, and resource use in newborn infants weighing 500 to 1500 g. N. Engl. J. Med. 330: 1476-1480 (1994)

10. Taghizadeh A., Reuynolds E.D.: Pathogenesis of bronchopulmonary dysplasia following hyaline membrane disease. Am. J. Pathol. 82: 241-264 (1976)

11. Palta M., Gabbert D., Weinstein M.R., Peters M.E.: Multivariate assessment of traditional risk factors for chronic lung disease in very low birth weight neonates. J. Pediatr. 119: 285-292 (1991)

12. Jobe A.H., Bancalari E.: Bronchopulmonary dysplasia. NICHD – NHLBI – ORD Workshop. Am. J. Respir. Crit. Care Med. 163: 1823-1829 (2001)

13. Gerdes J.S., Yoder M.C., Douglas S.D., Paul M., Harris M.C., Polin R.A.: Tracheal lavage and plasma fibronectin: relationship to respiratory distress syndrome and development of bronchopulmonary dysplasia. J. Pediatr. 108: 601-606 (1986)

14. Groneck P., Gotze-Speer B., Oppermann M.: Eiffert H, Speer CP: Association of pulmonary inflammation and increased microvascular permeability during the development of bronchopulmonary dysplasia: a sequential analysis of inflammatory mediators in respiratory fluids of high-risk preterm neonates. Pediatrics 93: 712-718 (1994)

15. Hannaford K., Todd D,A., Jeffery H., John E., Blyth K., Gilbert C,L,: Role of Ureaplasma urealyticum in lung disease of prematurity. Arch. Dis. Child Fetal. Neonatal. Ed. 81: F162-167 (1999)

16. Pierce M.R., Bancalari E.: The role of inflammation in the pathogenesis of bronchopulmonary dysplasia. Pediatr. Pulmonol. 19: 371-378 (1995)

17. Watterberg K.L., Carmichael D.F., Gerdes J.S., Werner S., Backstrom C., Murphy S.: Secretory leukocyte protease inhibitor and lung inflammation in developing bronchopulmonary dysplasia. J. Pediatr. 125: 264-269 (1994)

18. Watterberg K.L., Demers L.M., Scott S.M., Murphy S.: Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Pediatrics 97: 210-215 (1996)

19. Speer C.P.: Inflammation and bronchopulmonary dysplasia. Semin. Neonatol. 8:29-38 (2003)

20. Tammela O.K., Koivisto M.E.: Fluid restriction for prevention bronchopulmonary dysplasia? Reduced fluid intake during the first weeks of life improves the outcome of lowbirth weight infants. Acta Paediatr. 81: 207-212 (1992)

21. Van Marter L.J., Leviton A., Allred E.N., Pagano M., Kuban K.C.: Hydration during the first days of life and the risk of bronchopulmonary dysplasia in low birth weight infants. J. Pediatr. 116: 942-949 (1990)

22. Sosenko I.R.S., Kinter M.T., Roberts R.J.: Nutritional issues in chronic lung disease of premature infants. In: (Bland R.J., Coalson J.J., eds) Chronic Lung Disease in early Infancy. Pp. 285-296, Marcel Dekker, New York, 2000

23. Tyson J.E., Wright L.L.E., Oh W., Kennedy K.A., Mele L., Ehrenkranz R.A., et al.: Vitamin A supplementation for extremely – low – birth – weight infants. N. Engl. J. Med. 340: 1962-1968 (1999)

24. Hallman M.: Genetic influences and neonatal lung disease. Semin. Neonatol. 8: 19-27 (2003)

25. Gerhardt T., Hehre D., Feller R., Reifenberg L., Bancalari E.: Serial determination of pulmonary function in infants with chronic lung disease. J. Pediatr. 110: 448 (1987)

26. Greenspan J.S., DeGiulio P.A., Bhutaniv K.: Airway reactivity as determined by a cold air challenge in infants with bronchopulmonary dysplasia. J. Pediatr. 114: 452-454 (1989)

27. Watterberg K.L., Scott S.M.: Evidence of early adrenal insufficiency in babies who develop bronchopulmonary dysplasia. Pediatrics 95: 120-125 (1995)

28. Watterberg K.L., Gerdes J.S., Gifford K.L., Lin H.M.: Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. Pediatrics 104: 1258-1263 (1999)

29. Watterberg K.L., Scott S.M., Backstrom C., Gifford K.L., Cook K.L.: Links between early adrenal function and respiratory outcome in preterm infants: airway inflammation and patent ductus arteriosus. Pediatrics 15: 320-324 (2000)

30. Mallory G.B.,Jr, Chaney H., Mutich R.L., Motoyama E.K.: Longitudinal changes in lung function during the first three years of premature infants with moderate to severe bronchopulmonary dysplasia. Pediatr, Pulmonol, 11: 8 (1991)

31. Bhutani V.K., Abbasi S.: Long term pulmonary consequences in survivors with bronchopulmonary dysplasia. Clin. Perinatol. 19: 649-671 (1992)

32. Bancalari E.: Pathophysiology of Chronic Lung Disease. In (Polin R.A., Fox W.W., eds): Fetal and Neonatal Physiology. 2^nd ed., pp. 1188-1192, WB Saunders Company, Philadelphia, 1998

33. Ballard R.A., Nogee L.M., Beers M.F., Ballard P.L., Plane B.C., Polk E.L., et al.: Partial deficiency of surfactant protein B in an infant with chronic lung disease. Pediatrics 96: 1046 (1995)

34. Jackson J.C., Palmer S., Truog W.E., Standaert T.A., Murphy J.H., Hodson W.A.: Surfactant quantity and composition during recovery from hyaline membrane disease. Pediatr. Res. 20: 1243-7124 (1986)

35. LaGagnin L.B., Bowman L., Ma J.Y.C., Miles P.R.: Metabolic changes in alveolar type II cells after exposure to hydrogen peroxide. Am. J. Physiol. 259: L57-L65 (1990)

36. Crim C., Simon R.H.: Effects of oxygen metabolites on rat alveolar type II cell viability and surfactant metabolism. Lab. Invest. 58:.428-437 (1988)

37. Obladen M.: Alterations in surfactant composition. In: (Merritt T.A., Northway W.H., Boynton B.R., eds) Contemporary issues in fetal and neonatal medicine: Bronchopulmonary dysplasia. Pp. 131-141, Blackwell Scientific Publications, Palo Alto, CA, 1988

38. Batenburg J.J., Hallman M.: Developmental biochemistry of alveoli. In: (Scaerpelli E.M., ed.) Pulmonary physiology: Fetus-newborn-child-adolescent. 2nd ed., pp.106-139, Lea & Febiger, Piladelphia, 1999

39. Hallman M.: Antenatal diagnosis of lung maturity. In: (Robertson B., Van Golde L.M.G., Batenburg J.J., eds) Pulmonary Surfactant: from Molecular Biology to Clinical Practice. Pp. 425-458, Elsevier Science, Amsterdam, 1992

40. Pitkainen O.M., Hallman M., Andersson S.M.: Correlation of free oxygen radical induced lipid peroxidation with outcome in very low birth weight infants. J. Pediatr. 116: 760-764 (1990)

41. Horowitz S., Watkins R.H., Auten R.L.,Jr, Mercier C.E., Cheng E.R.: Differential accumulation of surfactant protein A, B, and C mRNAs in two epithelial cell types of hyperoxic lung. Am. J. Respir. Cell. Mol. Biol. 5: 511-515 (1991)

42. King R.J., Coalson J.J., DeLemos R.A., Gerstmann D.R., Seidner S.R.: Surfactant protein-A deficiency in a primate model of bronchopulmonary dysplasia. Am. J. Respir. Crit. Care Med.151:1989-1997 (1995)

43. Allred T.F., Mercer R.R., Thomas R.F., Deng H.,  Auten R.L.: Brief 95% O2 exposure effects on surfactant protein and mRNA in rat alveolar and bronchiolar epithelium. Am. J. Physiol. 276: L999-1009 (1999)

44. Coalson J.J., King R.J., Yang F., Winter V., Whitsett J.A., Delemos R.A., et al.: SP-A deficiency in a primate model of bronchopulmonary dysplasia with infection. Am. J. Respir. Crit. Care Med. 151: 854-866 (1995)

45. Savani R.C., Godinez R.I., Godinez M.H., Wentz E., Zaman A., Cui Z., et al.: Respiratory distress after intratracheal bleomycin: selective deficiency of surfactant proteins B and C. Am. J. Physiol. Lung Cell. Mol. Physiol. 281: L685-696 (2001)

46. Beers M.F., Hamvas A., Moxley M.A., Gonzales L.W., Guttentag S.H., Solarin K.O., et al.: Pulmonary surfactant metabolism in infants lacking surfactant protein B. Am. J. Respir. Cell. Mol. Biol. 22: 380-391 (2000)

47. Hallman M., Merritt T.A., Akino T., Bry K.: Surfactant protein A, phosphatidylcholine, and surfactant inhibitors in epithelial lining fluid. Correlation with surface activity, severity of respiratory distress syndrome, and outcome in small premature infants. Am. Rev. Respir. Dis. 144:.1376-1384 (1991)

48. Auten R.L., Notter R.H., Kending J., Davis J.M., Shapiro D.L.: Surfactant treatment of full-term newborns with respiratory failure. Pediatrics 87: 101-107 (1991)

49. Jeffries A.L., Coates G., O’Brodovich H.: Pulmonary epithelial permeability in hyaline membrane disease. N. Engl. J. Med. 311: 1075-1080 (1984)

50. Ikegami M., Jacobs H., Jobe A.: Surfactant function in respiratory distress syndrome. J. Pediatr. 102: 443-447 (1983)

51. Clement A., Masliah J., Housset B., Just J., Garcia J., Grimfeld A., et al.: Decreased phospatidylcholine content in bronchoalveolar lavage fluids of children with bronchopulmonary dysplasia: a preliminary investigation. Pediatr. Pulmonol. 3: 67-70 (1987)

52. Merrill J.D., Ballard R.A., Godinez R.I.: Surfactant function and composition in premature infants with lung disease. Pediatr. Res. 51: 347A (2002)

53. Singh A.J., Bronshtein V., Khashu M., Lee K., Potts J.E., Friel J., Chessex P.: Vitamin A is systemically bioavailable following intratracheal administration with surfactant in an animal model of newborn respiratory distress. Pediatr. Res. 2010 (In press)

54. Yeh T.F., Lin H.C., Chang C.H., Wu T.S., Su B.H., Li T.C., Pyati S., Tsai C.H.: Early intratracheal instillation of budesonide using surfactant as vehicle to prevent chronic lung disease in preterm infants: a pilot study. Pediatrics 121(5): e1310-1318 (2008)

55. Kuo H.T., Lin H.C., Tsai H.C., Chouc I.C., Yeh T.F.: A follow-up study of preterm infants given budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants. J. Pediatr. 2010 (In press)

56. Ballard R.A., Truog W.E., Cnaan A., Martin R.J., Ballard P.L., Merrill J.D., Walsh M.C., Durand D.J., Mayock D.E., Eichenwald E.C., Null D.R., Hudak M.L., Puri A.R., Golombek S.G., Courtney S.E., Stewart D.L., Welty S.E., Phibbs R.H., Hibbs A.M., Luan X., Wadlinger S.R., Asselin J.M., Coburn C.E., NO CLD Study Group: Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N. Engl. J. Med. 355: 343-353 (2006)

57. Whitsett J.A., Wert S.E., Weaver T.E.: Alveolar surfactant homeostasis and the pathogenesis of pulmonary disease. Annu. Rev. Med. 61: 105-119 (2010)

58. Wert S.E., Whitsett J.A., Nogee L.M.: Genetic disorders of surfactant dysfunction. Pediatr. Dev. Pathol. 12: 257-274 (2009)

pharmakonpress[at]pharmakonpress[.]gr

pharmakonpress[at]pharmakonpress[.]gr